SCHEMBL177157

SCHEMBL177157

CCCCCCCCc1ccc(I)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.63
ADRA2A P08913 2/20 0.63
ADORA3 P0DMS8 2/20 0.63
TACR2 P21452 2/20 0.63
SLC6A2 P23975 2/20 0.63
SLC6A4 P31645 2/20 0.63
SLC6A3 Q01959 2/20 0.63
ALDH1A1 P00352 2/20 0.63
HSD17B10 Q99714 2/20 0.63
KDM4E B2RXH2 1/20 0.63
LMNA P02545 1/20 0.63
SHBG P04278 1/20 0.63
TP53 P04637 1/20 0.63
CYP3A4 P08684 1/20 0.63
HSPD1 P10809 1/20 0.63
ADRB3 P13945 1/20 0.63
HTR2C P28335 1/20 0.63
HSPE1 P61604 1/20 0.63
HIF1A Q16665 1/20 0.63
TST Q16762 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27627903 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL10587047 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL29162246 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL27994729 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL9850692 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL282601 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL9850855 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL29162255 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL7466292 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2
SCHEMBL14193847 1.00 ESR1 (0.63) ESR1ADRA2AADORA3TACR2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) 2025-01-16 US disclosed
WO-2024260416-A1 ORGANIC COMPOUND, PREPARATION METHOD THEREFOR, AND ELECTRONIC DEVICE TCL科技集团股份有限公司 2024-12-26 WO disclosed
CN-119176817-A Organic compound, preparation method thereof and electronic device TCL科技集团股份有限公司 2024-12-24 CN disclosed
EP-4444694-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES Peking University (CN) 2024-10-16 EP disclosed
CN-118510752-A Compounds for the treatment of bacterial diseases and methods of use thereof 北京大学 2024-08-16 CN disclosed
WO-2023104017-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES PEKING UNIVERSITY (CN) 2023-06-15 WO disclosed
WO-2023104017-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES PEKING UNIVERSITY (CN) 2023-06-15 WO disclosed
US-20220389016-A1 COMPOUND AND METHOD FOR PRODUCING COMPOUND FUJIFILM CORPORATION (JP) 2022-12-08 US disclosed
US-20200369901-A1 DISPERSION, INK JET RECORDING METHOD, RECORDED MATERIAL, AND COMPOUND FUJIFILM CORPORATION (JP) 2020-11-26 US disclosed
US-9707205-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2017-07-18 US disclosed
US-7122711-B2 Method for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-10-17 US disclosed
US-20060124923-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 US disclosed
US-20060125009-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 US disclosed
CN-1716094-A Radiation sensitive resin composition SUMITOMO CHEM ENG (JP) 2006-01-04 CN disclosed
US-20030158419-A1 Method for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2003-08-21 US disclosed
EP-1312605-A1 Method for producing biaryl compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-05-21 EP disclosed
CN-1102623-C Curing process for cationically photocurable formulation CIBA SC HOLDING AG (CH) 2003-03-05 CN disclosed
US-6007739-A FOR DISPLAY OF A CLOCK, A CALCULATOR, A WORD PROCESSOR, A SMALL TV SET; CAN BE DRIVEN AT A HIGH SPEED AT A LOW VOLTAGE SHARP KABUSHIKI KAISHA (JP) 1999-12-28 US disclosed
CN-1225109-A Curing process for cationically photocurable formulation CIBA SC HOLDING AG (CH) 1999-08-04 CN disclosed
EP-0517498-A1 Liquid crystal compounds and compositions SANYO CHEMICAL INDUSTRIES LTD. (JP) 1992-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389016-A1 COMPOUND AND METHOD FOR PRODUCING COMPOUND DHPS, AZI2, CYP51A1 ESR1 2004/4885ADRA2A 2685/4885ADORA3 1824/4885
US-20250019341-A1 COMPOUNDS AND METHOD OF USE THEREOF FOR TREATING BACTERIAL DISEASES TLR3, CGAS, NOD2 ESR1 3851/4885ADRA2A 4581/4885ADORA3 3460/4885
US-20030158419-A1 Method for producing biaryl compound B2M, BMI1, CYP2W1 ESR1 1343/4885ADRA2A 1855/4885ADORA3 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.